featured
Incidence, Multidisciplinary Management, and Prognostic Implication of Ribociclib-Induced Cutaneous Adverse Events in Patients With HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
Oncologist 2024 Jan 18;[EPub Ahead of Print], RG Borroni, M Bartolini, M Gaudio, F Jacobs, C Benvenuti, R Gerosa, P Tiberio, SAAM Manara, A Solferino, A Santoro, R De SanctisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.